When does ICH E6(R3) take effect?
ICH adopted the E6(R3) principles and Annex 1 on 6 January 2025, and each regulator then brings it into force on its own timeline (ICH E6(R3), document history).
In the EU the principles and Annex 1 came into effect on 23 July 2025, and FDA published E6(R3) as final guidance in September 2025; Annex 2 was adopted by ICH on 3 June 2026 and takes effect in the EU on 15 January 2027 (EMA, ICH E6 scientific guideline page; FDA, E6(R3) guidance page).
The dates, by part and by region
- ICH: the principles and Annex 1 reached Step 4 and were adopted on 6 January 2025 (ICH E6(R3), document history).
- European Union: the principles and Annex 1 have a legal effective date of 23 July 2025 (EMA, ICH E6 scientific guideline page).
- United States: FDA lists E6(R3) as final guidance issued in September 2025 under docket FDA-2023-D-1955 (FDA, E6(R3) guidance page). FDA guidance describes the agency's current thinking; the binding requirements remain the regulations in 21 CFR.
- Annex 2, on trials that use decentralized elements, pragmatic elements and real world data: adopted by ICH on 3 June 2026 and by the CHMP on 25 June 2026, effective in the EU on 15 January 2027 (EMA, ICH E6 scientific guideline page).
- Other regions adopt on their own schedules. Check your own regulator's site for the date that applies to you.
What this means for a site that is running trials today
Sponsors write protocols and monitoring plans against the version their regulators apply, so a site can see E6(R2) language on an older study and E6(R3) language on a new one. The practical move is to train staff on E6(R3) now, because new protocols, sponsor SOPs and inspection questions are already moving to it.
E6(R3) changes the emphasis more than the core duties. It builds quality into trial design (ICH E6(R3) Principle 6), asks for processes proportionate to the risks to participants and to the reliability of results (ICH E6(R3) Principle 7), and expands data governance and computerised systems into a section of their own (ICH E6(R3) 4.3).
What to do now
- Update GCP training for every person on a delegation log to E6(R3), and keep the record with its completion date.
- Read your sponsors' updated SOPs and monitoring plans, which will cite the new section numbers.
- Check how your site defines source records before each trial starts, which E6(R3) now asks the investigator to do (ICH E6(R3) 2.12.2).
- If you run trials with remote visits, home nursing or real world data, start on Annex 2 before it takes effect.
Questions people also ask
Is ICH E6(R3) in effect in the United States?
FDA issued E6(R3) as final guidance in September 2025 (FDA, E6(R3) guidance page). Guidance is not itself a regulation: the enforceable requirements for investigators are in 21 CFR parts 50, 56 and 312, and E6(R3) describes how FDA expects good clinical practice to be met.
Does E6(R3) replace E6(R2)?
Yes, for the regions that adopt it. EMA describes the principles and Annex 1 as able to serve as a replacement for E6(R2) (EMA, ICH E6 scientific guideline page).
What is ICH E6(R3) Annex 2?
An annex with additional considerations for trials that use decentralized elements, pragmatic elements or real world data sources. It applies alongside the principles and Annex 1, and in the EU it takes effect on 15 January 2027 (EMA, ICH E6 scientific guideline page).
Do I need new GCP training because of E6(R3)?
Most sponsors and institutions now expect GCP training that covers E6(R3). How often training must be renewed is set by the sponsor or institution, not by the guideline.
Primary sources
- ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
- ICH E6 Good clinical practice: scientific guideline (European Medicines Agency): https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline
- E6(R3) Good Clinical Practice, final guidance (U.S. Food and Drug Administration): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp
Last reviewed
2026-11-12